249 related articles for article (PubMed ID: 26542177)
21. [Chemotherapy of malignant inoperable gliomas. The association of fotemustine-cisplatine-etoposide as neoadjuvants].
Frenay M; Lebrun C; Lonjon M; Marcy PY; Paquis P
Rev Neurol (Paris); 2000 Jan; 156(1):53-8. PubMed ID: 10693259
[TBL] [Abstract][Full Text] [Related]
22. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
24. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
25. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab use for recurrent high-grade glioma at McGill University Hospital.
Sahebjam S; Garoufalis E; Guiot MC; Muanza T; Del Maestro R; Petrecca K; Sharma R; Kavan P
Can J Neurol Sci; 2013 Mar; 40(2):241-6. PubMed ID: 23419575
[TBL] [Abstract][Full Text] [Related]
27. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.
Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V
Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.
Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E
Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188
[TBL] [Abstract][Full Text] [Related]
29. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
[TBL] [Abstract][Full Text] [Related]
30. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
[TBL] [Abstract][Full Text] [Related]
31. Lecture: fotemustine in brain tumors.
Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
[TBL] [Abstract][Full Text] [Related]
32. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Hassler MR; Ackerl M; Flechl B; Sax C; Wöhrer A; Widhalm G; Dieckmann K; Hainfellner J; Preusser M; Marosi C
Anticancer Drugs; 2014 Jul; 25(6):723-8. PubMed ID: 24441743
[TBL] [Abstract][Full Text] [Related]
34. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
35. The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.
Lombardi G; Della Puppa A; Zustovich F; Pambuku A; Farina P; Fiduccia P; Roma A; Zagonel V
Biomed Res Int; 2014; 2014():678191. PubMed ID: 24812626
[TBL] [Abstract][Full Text] [Related]
36. A case series of salvage CCNU in high-grade glioma who have previously received temozolomide from a tertiary care institute in Mumbai.
Patil VM; Abhinav R; Tonse R; Epari S; Gupta T; Jalali R
Indian J Cancer; 2016; 53(4):558-561. PubMed ID: 28485350
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA
J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.
Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N
Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
40. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.
Leyvraz S; Piperno-Neumann S; Suciu S; Baurain JF; Zdzienicki M; Testori A; Marshall E; Scheulen M; Jouary T; Negrier S; Vermorken JB; Kaempgen E; Durando X; Schadendorf D; Gurunath RK; Keilholz U
Ann Oncol; 2014 Mar; 25(3):742-746. PubMed ID: 24510314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
